Globenewswire·2025-04-21 11:00Core Viewpoint - Immunovant, Inc. is entering a new growth phase with leadership changes and expanded development of IMVT-1402 into Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) [1][2] Leadership Changes - Eric Venker, M.D. has been appointed as the new CEO of Immunovant, bringing over 20 years of clinical and operational experience [2][6] - Pete Salzmann, M.D. has retired from his role as CEO and Director, while Tiago Girao has been appointed as the new CFO [2][6] - George Migausky has stepped down from the board, with Robert Susman and Jacob Bauer joining [3] Strategic Transition - The leadership changes are part of a broader strategic transition, with Roivant increasing its operational involvement and oversight of Immunovant [2][6] - Development activities for batoclimab are concluding, while those for IMVT-1402 are ramping up [2][6] Clinical Development Updates - The IND for IMVT-1402 in SjD has been cleared, marking it as the fifth indication for the drug, with a study expected to initiate in summer 2025 [6] - A proof-of-concept study for IMVT-1402 in CLE has been initiated, based on promising efficacy data from previous studies [6] - Current cash balance is sufficient to support the announced indications through the expected readout for Graves' Disease in 2027 [6] Market Need - Sjögren's Disease is characterized by severe dryness and has no approved therapies specifically targeting it, indicating a significant market opportunity [7] - Cutaneous Lupus Erythematosus (CLE) has a high unmet need, with up to 50% of patients not optimally managed by current therapies, and no new therapies approved in over 50 years [8]